MedTrace Logo

Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults

NCT06873204 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-06-29

No results posted yet for this study

Summary

The importance of the gut microbiota for general health has been recently elucidated, but little is known about the impact of different types of nutrients on the gut microbiota. The soluble fiber in cereal by-products, arabinoxylan (AX), is known to be beneficial for generally promoting gut health. However, it is unclear whether consuming rice bran (RB), the source of AX, is equally helpful or better than consuming the extracted form of AX. This study aims to reveal the potential benefit of insoluble cereal bran fiber ingredients by comparing the effect of soluble arabinoxylan fiber alone and the mostly insoluble rice bran fiber, containing arabinoxylan, on intestinal health and gut microbiota. A placebo (maltodextrin) will be used as a control, with no significant changes expected in this group for the evaluated outcomes.

Participants will:

* Consume two different fiber supplements (soluble arabinoxylan or stabilized rice bran) as well as a placebo (maltodextrin) for 3 weeks each, separated by a 2-week washout period.
* Provide blood and stool samples at six different time points.
* Complete a food and gastrointestinal symptom diary during the intervention periods.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Soluble Arabinoxylan

10 grams of soluble arabinoxylan diluted in 200 mL of water, twice daily for 3 consecutive weeks.

DIETARY_SUPPLEMENT

Rice Bran

10 grams of rice bran fiber diluted in 200 mL of water, twice daily for 3 consecutive weeks.

DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

10 grams of maltodextrin diluted in 200 mL of water, twice daily for 3 consecutive weeks.

Sponsors & Collaborators

  • Rural Development Administration (RDA) of the Republic of Korea

    collaborator UNKNOWN

  • Purdue University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06873204 on ClinicalTrials.gov